NeuroSense reports additional data from its Phase 2b PARADIGM trial of PrimeC

NeuroSense Therapeutics reports additional positive data from its six-month double-blind Phase 2b PARADIGM trial of NeuroSense’s lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis, or ALS. The PARADIGM trial’s secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. Consistent with the previously reported results, PrimeC displayed a clinically meaningful effect on various aspects of patients’ quality of life, including mental and physical health. Moreover, analyses pertaining to survival outcomes emphasized the implications of PrimeC intervention in mitigating disease progression and burden. PrimeC achieved an improvement in complication-free survival compared to placebo, reducing the risk of ALS disease complications or death by up to 53%. These survival analyses observe time from participant randomization to death from any cause or respiratory insufficiency, or time to hospitalization due to ALS-related complications or advancements in MiToS or King’s stages.